vorasidenib
servier
['vorasidenib', 'indigo']
 plenary #asco23 indigo trial: a phase iii trial with vorasidenib vs placebo for idh1/2 positive residual or recurrent glioma &gt; improved pfs (27.7 vs 11.1 mo; hr 0.39) @ 
Assistant Prof | Thoracic Oncology & Phase-I @karmanoscancer | EIC @BTFCancerNews | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb | Tweets my own